您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2021, Vol. 59 ›› Issue (5): 46-51,67.doi: 10.6040/j.issn.1671-7554.0.2021.0262

• 医学病毒的基础与临床研究进展专题 • 上一篇    下一篇

乙型肝炎病毒母婴传播预防研究进展

范玉琛*()   

  1. 山东大学齐鲁医院肝病科 山东大学肝病研究所, 山东 济南 250012
  • 收稿日期:2021-03-12 出版日期:2021-05-10 发布日期:2021-06-01
  • 通讯作者: 范玉琛 E-mail:fanyuchen@sdu.edu.cn; pyfanyuchen@126.com
  • 作者简介:范玉琛，医学博士，博士后，山东大学齐鲁医院肝病科副主任(主持工作)，副主任医师，泰山学者青年专家，山东大学齐鲁医院杰出青年人才，硕士研究生导师，兼任中华医学会医学病毒学分会临床病毒学组委员，中国医师协会感染科医师分会青年委员，中国医药教育协会肝脏病学专业委员会委员，国家肿瘤微创治疗产业技术创新联盟肝病专业委员会委员，山东省医学会医学病毒学分会青年学组副组长，山东省医学会感染病学分会肝衰竭学组副组长，山东省医学会肝病学分会青年学组委员，《国际流行病学传染病学杂志》第三届通讯编委，《Hepatitis Monthly》杂志副主编，《The Journal of Clinical and Translational Hepatology》杂志副主编，《Canadian Journal of Gastroenterology and Hepatology》编委，《Gut》、《Alimentary Pharmacology & Therapeutics》等期刊审稿人，国家自然科学基金评审专家。主要研究方向为乙型肝炎的免疫机制及临床诊断和预后的分子标志物预警预测研究等。在国内外核心期刊发表论文120余篇，其中SCI收录110篇，以第一作者或通讯作者在《Clinical Gastroenterology and Hepatology》、《Applied Catalysis B: Environmental》、《Alimentary Pharmacology & Therapeutics》等发表SCI论文22篇，单篇最高影响因子16.68。主持国家重点研发计划1项，国家自然科学基金2项，省部级项目3项，校级项目3项，山东大学“光动力医学”青年交叉创新群体核心成员，累计经费900万元。以研究骨干参与国家科技重大专项、国家自然科学基金等省部级项目10余项。以第二位获得山东省科技进步二等奖2项
  • 基金资助:
    国家自然科学基金(81970522);山东省泰山学者青年专家专项经费(tsqn202103169)

Current progress on prevention of mother to child transmission of hepatitis B virus

Yuchen FAN*()   

  1. Department of Hepatology, Qilu Hospital of Shandong University; Institute of Hepatology, Shandong University, Jinan 250012, Shandong, China
  • Received:2021-03-12 Online:2021-05-10 Published:2021-06-01
  • Contact: Yuchen FAN E-mail:fanyuchen@sdu.edu.cn; pyfanyuchen@126.com

RichHTML

22

PDF (PC)

603

摘要：

乙型肝炎病毒(HBV)感染是全球性的公共安全威胁，其导致的慢性乙型肝炎(CHB)、肝硬化、肝癌及肝功能衰竭等严重危害人类生命健康。母婴传播是HBV传播的主要方式之一，通过有效干预阻断HBV的母婴传播对于降低HBV感染率、减轻HBV相关疾病负担具有重要意义。随着我国经济和医疗水平的不断发展，预防HBV母婴传播的措施不断完善，使我国HBV流行率大幅降低。论文就我国预防HBV母婴传播的临床指南和规范进行总结，并对该领域的热点问题和相关进展做一综述。

关键词: 肝炎病毒, 乙型, 母婴传播阻断, 乙型肝炎免疫球蛋白, 抗病毒药, 临床管理

Abstract:

Hepatitis B virus (HBV) infection is a global public threat, which leads to chronic hepatitis B (CHB), liver cirrhosis, liver cancer and liver failure. Mother to child transmission is one of the main ways of HBV transmission. It is of great significance to block the mother to child transmission of HBV through effective intervention to reduce the infection rate of HBV and reduce the burden of HBV related diseases. With the continuous development of China's economy and medical level, measures to prevent mother to child transmission of HBV are constantly improved, which greatly reduces the prevalence of HBV in China. This article summarizes the clinical guidelines and norms for the prevention of mother to child transmission of HBV in China, and summarizes the hot issues and related progress in this field.

Key words: Hepatitis B virus, Interruption of mother to child transmission, Hepatitis B immunoglobulin, Antiviral drugs, Clinical management

中图分类号: 

  • R512.6

图1

乙型肝炎病毒母婴传播防治流程图"

1 Liu J , Liang W , Jing W , et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97 (3): 230- 238.
doi: 10.2471/BLT.18.219469
2 Cui F , Shen L , Li L , et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23 (5): 765- 772.
doi: 10.3201/eid2305.161477
3 中华医学会感染病学分会, GRADE中国中心. 中国乙型肝炎病毒母婴传播防治指南(2019年版)[J]. 中华临床感染病杂志, 2019, 37 (7): 388- 396.
4 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南[J]. 中华传染病杂志, 2005, 23 (6): 421- 431.
doi: 10.3760/j.issn:1000-6680.2005.06.021
5 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版)[J]. 中华肝脏病杂志, 2011, 19 (1): 13- 24.
doi: 10.3760/cma.j.issn.1007-3418.2011.01.007
Chinese Society of Hepatology and Chinese Society of Infectious Diseases , Chinese Medical Association . The guideline of prevention and treatment for chronic hepatitis B (2010 version)[J]. Chinese Journal of Hepatology, 2011, 19 (1): 13- 24.
doi: 10.3760/cma.j.issn.1007-3418.2011.01.007
6 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版)[J]. 中国肝脏病杂志(电子版), 2015, 7 (3): 1- 18.
Chinese Society of Hepatology and Chinese Society of Infectious Diseases , Chinese Medical Association . The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. Chinese Journal of Liver Diseases(Electronic Version), 2015, 7 (3): 1- 18.
7 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华肝脏病杂志, 2019, 27 (12): 938- 961.
doi: 10.3760/cma.j.issn.1007-3418.2019.12.007
Chinese Society of Infectious Diseases Chinese Medical Association; , Chinese Society of Hepatology Chinese Medical Association . The guidelines of prevention and treatment for chronic hepatitis B (2019 version)[J]. Chinese Journal of Hepatology, 2019, 27 (12): 938- 961.
doi: 10.3760/cma.j.issn.1007-3418.2019.12.007
8 中华医学会妇产科学分会产科学组, 中华医学会围产医学分会. 乙型肝炎病毒母婴传播预防临床指南(2020)[J]. 中华妇产科杂志, 2020, 55 (5): 291- 299.
doi: 10.3760/cma.j.cn112141-20200213-00101
9 崔富强, 庄辉. 我国新生儿乙型肝炎母婴阻断成就和展望[J]. 中国病毒病杂志, 2019, 9 (5): 321- 326.
CUI Fuqiang , ZHUANG Hui . Achievements and prospects for preventing mother-to-child transmission of hepatitis B virus in newborns in China[J]. Chinese Journal of Viral Diseases, 2019, 9 (5): 321- 326.
10 贾继东, 侯金林, 魏来, 等. 《慢性乙型肝炎防治指南(2019年版)》新亮点[J]. 中华肝脏病杂志, 2020, 28 (1): 21- 23.
doi: 10.3760/cma.j.issn.1007-3418.2020.01.006
JIA Jidong , HOU Jinlin , WEI Lai , et al. Highlights of guidelines of prevention and treatment for chronic hepatitis B (2019 version)[J]. Chinese Journal of Hepatology, 2020, 28 (1): 21- 23.
doi: 10.3760/cma.j.issn.1007-3418.2020.01.006
11 European Association for the Study of the Liver . EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67 (2): 370- 398.
doi: 10.1016/j.jhep.2017.03.021
12 Terrault NA , Lok ASF , McMahon BJ , et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67 (4): 1560- 1599.
doi: 10.1002/hep.29800
13 周乙华, 李彤, 庄辉. 对《中国乙型肝炎病毒母婴传播防治指南(2019年版)》的商榷[J]. 中华传染病杂志, 2020, 38 (1): 49- 50.
doi: 10.3760/cma.j.issn.1000-6680.2020.01.007
14 徐陈瑜, 陈廷美. 对《中国乙型肝炎病毒母婴传播防治指南(2019年版)》的若干探讨意见[J]. 肝脏, 2020, 25 (3): 228- 230.
doi: 10.3969/j.issn.1008-1704.2020.03.003
15 Mugwanya KK , Hendrix CW , Mugo NR , et al. Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption[J]. PLoS Med, 2016, 13 (9): e1002132.
doi: 10.1371/journal.pmed.1002132
16 Mirochnick M , Taha T , Kreitchmann R , et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life[J]. J Acquir Immune Defic Syndr, 2014, 65 (1): 33- 41.
doi: 10.1097/QAI.0b013e3182a921eb
17 Waitt C , Taha T , Olagunju A , Nakalema S , et al. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs[J]. J Antimicrob Chemother, 2018, 73 (4): 1013- 1019.
doi: 10.1093/jac/dkx507
18 中华医学会肝病学分会. 感染乙型肝炎病毒的育龄女性临床管理共识[J]. 中国病毒病杂志, 2018, 8 (3): 164- 169.
Chinese Society of Hpatology, Chinese Medical Association , et al. Consensus on the management of hepatitis B virus infection in women of childbearing age[J]. Chinese Journal of Viral Diseases, 2018, 8 (3): 164- 169.
19 Sakai K , Ueda A , Hasegawa M , et al. Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy: two cases and a literature review[J]. Int J Hematol, 2018, 108 (2): 203- 207.
doi: 10.1007/s12185-017-2397-8
20 Sandberg-Wollheim M , Alteri E , Moraga MS , et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy[J]. Mult Scler, 2011, 17 (4): 423- 430.
doi: 10.1177/1352458510394610
21 Hiratsuka M , Minakami H , Koshizuka S , et al. Administration of interferon-alpha during pregnancy: effects on fetus[J]. J Perinat Med, 2000, 28 (5): 372- 376.
22 Labarga P , Pinilla J , Cachorro I , et al. Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy[J]. Reprod Toxicol, 2007, 24 (3-4): 414- 416.
doi: 10.1016/j.reprotox.2007.07.002
23 Castillo E , Murphy K , van Schalkwyk J . No. 342-hepatitis B and pregnancy[J]. J Obstet Gynaecol Can, 2017, 39 (3): 181- 190.
doi: 10.1016/j.jogc.2016.11.001
24 Wu Y , Liu J , Feng Y , et al. Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: systematic review and network meta-analysis[J]. Hepatol Int, 2020, 14 (2): 180- 189.
doi: 10.1007/s12072-020-10026-0
25 Song J , Yang F , Wang S , et al. Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: a meta-analysis[J]. J Viral Hepat, 2019, 26 (3): 397- 406.
26 Zhang H , Pan CQ , Pang Q , et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice[J]. Hepatology, 2014,
doi: 10.1002/hep.27034
27 Jourdain G , Ngo-Giang-Huong N , Harrison L , et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B[J]. N Engl J Med, 2018, 378 (10): 911- 923.
doi: 10.1056/NEJMoa1708131
28 Pan CQ , Duan Z , Dai E , et al. China study group for the mother-to-child transmission of hepatitis B: tenofovir to prevent hepatitis B transmission in mothers with high viral load[J]. N Engl J Med, 2016, 374 (24): 2324- 2434.
doi: 10.1056/NEJMoa1508660
29 Li J , Chang MS , Tran TT , et al. Management of chronic hepatitis B in pregnancy[J]. J Clin Gastroenterol, 2017, 51 (9): 789- 795.
doi: 10.1097/MCG.0000000000000908
30 Brown Jr RS , McMahon BJ , Lok ASF , et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis[J]. Hepatology, 2016, 63 (1): 319- 333.
doi: 10.1002/hep.28302
31 Sali S , Darvishi M , GhasemiAdl M , et al. Comparing the efficacy and safety of treating chronic hepatitis B infection during pregnancy with lamivudine, telbivudine, and tenofovir: a Meta-analysis[J]. J Clin Transl Hepatol, 2019, 7 (3): 197- 212.
32 咸建春, 周乙华. 对《中国乙型肝炎病毒母婴传播防治指南(2019年版)》中育龄妇女抗病毒治疗期间意外妊娠推荐意见的评价[J]. 临床肝胆病杂志, 2020, 36 (2): 301- 302.
doi: 10.3969/j.issn.1001-5256.2020.02.010
XIAN Jianchun , ZHOU Yihua , et al. Comments on the recommendtions for unintended pregnancy during antiviral therapy in women of childbearing age in 2019 Chinese practice guideline for the prevention of hepatitis B virus mother-to-child transmission[J]. Journal of Clinical Hepatology, 2020, 36 (2): 301- 302.
doi: 10.3969/j.issn.1001-5256.2020.02.010
33 Gu Y , Ru T , Zhou YH , et al. Adefovir as a possible teratogen: evidence from paternal exposure[J]. Dig Liver Dis, 2014, 46 (12): 1134- 1135.
doi: 10.1016/j.dld.2014.08.035
34 Peng S , Wan Z , Liu T , et al. Cesarean section reduces the risk of early mother-to-child transmission of hepatitis B virus[J]. Dig Liver Dis, 2018, 50 (10): 1076- 1080.
doi: 10.1016/j.dld.2018.05.004
35 Pan CQ , Zou HB , Chen Y , et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants[J]. Clin Gastroenterol Hepatol, 2013, 11 (10): 1349- 1355.
doi: 10.1016/j.cgh.2013.04.026
36 Yang M , Qin Q , Fang Q , et al. Cesarean section to prevent mother-to-child transmission of hepatitis B virus in China: a meta-analysis[J]. BMC Pregnancy Childbirth, 2017, 17 (1): 303.
doi: 10.1186/s12884-017-1487-1
[1] 徐冰,王淑琴,陶佩珍,李玉环 . 重组集成干扰素α体外抗病毒的药效学研究[J]. 山东大学学报(医学版), 2006, 44(8): 831-833.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 索东阳,申飞,郭皓,刘力畅,杨惠敏,杨向东. Tim-3在药物性急性肾损伤动物模型中的表达及作用机制[J]. 山东大学学报 (医学版), 2020, 1(7): 1 -6 .
[2] 马青源,蒲沛东,韩飞,王超,朱洲均,王维山,史晨辉. miR-27b-3p调控SMAD1对骨肉瘤细胞增殖、迁移和侵袭作用的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 32 -37 .
[3] 徐玉香,刘煜东,张蓬,段瑞生. 101例脑小血管病患者脑微出血危险因素的回顾性分析[J]. 山东大学学报 (医学版), 2020, 1(7): 67 -71 .
[4] 罗昕,何兵,聂清生,侯震波,董军,李玉花,曾祥芹,刘伟,孔德民,曹金凤. 磁共振扩散加权成像单指数模型与扩散峰度成像模型在61例肾透明细胞癌分级中的对比[J]. 山东大学学报 (医学版), 2020, 1(7): 89 -95 .
[5] 张迪,于猛,刘霞. 神经调控技术简述[J]. 山东大学学报 (医学版), 2020, 1(8): 50 -60 .
[6] 张伟,谭文浩,李贻斌. 基于深度强化学习的四足机器人运动控制发展现状与展望[J]. 山东大学学报 (医学版), 2020, 1(8): 61 -66 .
[7] 陈安静,张训. 靶向小类泛素化修饰的胶质瘤治疗新策略[J]. 山东大学学报 (医学版), 2020, 1(8): 88 -94 .
[8] 张洪彬,赵寒辉,王素霞,周鹏,贺青卿,王延群,丁伟平,柳刚. 303例甲状旁腺切除术围术期观察及术后严重低钙血症危险因素分析[J]. 山东大学学报 (医学版), 2020, 1(9): 14 -20 .
[9] 孙薏丰,高玉,梁永媛,高杨. CPLX2在30例肝癌组织的表达及其对体外细胞增殖与侵袭的影响[J]. 山东大学学报 (医学版), 2020, 1(9): 34 -39 .
[10] 栗英林,宋道庆,徐忠华. 应用生物信息学方法分析肾透明细胞癌中FKBP11的表达[J]. 山东大学学报 (医学版), 2020, 1(9): 45 -51 .
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发